Daiichi Sankyo on Monday announced that its Savaysa (edoxaban) tablets are now available in pharmacies across the United States. The drug was granted approval from the Food and Drug Administration on Jan. 8 and is used to reduce the risk of stroke and systemic embolism in patients who have a non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism, the company said.
Daiichi Sankyo Co., Limited on Friday announced that the Food and Drug Administration has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor that reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Low-dose aspirin lowers the occurrence of new venous blood clots — and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in Monday's issue of Circulation.
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.
Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a preventive treatment for deep vein thrombosis, which can lead to pulmonary embolism for patients who have had hip or knee replacement surgery.
Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.